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Femoropopliteal Lesions
So Many Options, Little Consensus*Mehdi H. Shishehbor, DO, MPH, PHDT he ﬁrst published arterial endovascular pro-cedure was performed by Dr. Charles Dotterin 1964 in the superﬁcial femoral artery (1).
Since then, the femoropopliteal segment has posed
many challenges and opportunities for inventors, in-
dustry, physicians, and, most importantly, patients.
The evolution in techniques and technologies over
the last decade has led to an increase in endovascular
procedures with a reduction in the rates of major
amputation (2). Many devices have been developed;
some are currently in use, but others are no longer
available (3). Of these, balloons and stents haveSEE PAGE 2329stood the test of time; yet, they too have evolved.
Despite the many endovascular treatment options
for femoropopliteal lesions, little consensus exists
regarding the best treatment algorithm (Figure 1). To
add to this complexity, 2 drug-coated balloons
(DCBs) have recently been approved in the United
States on the basis of 12 months of safety and efﬁcacy
(4,5). Overall, this technology has received a warm
welcome from most physicians; however, concerns
about late catch-up and long-term patency have
remained (6). To that end, in this issue of the Journal,
Laird et al. (7) present 24-month data on the safety
and efﬁcacy of the IN.PACT SFA randomized clinical
trial.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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miral DCB (Medtronic, Santa Rosa, California) versus
standard angioplasty in 331 patients with Rutherford
class 2 to 4 femoropopliteal lesions with mean lesion
length of 8.94 cm. Primary patency was deﬁned as
freedom from clinically driven target lesion revascu-
larization (CD-TLR) or freedom from restenosis as
determined by peak systolic velocity ratio of #2.4.
Overall, DCB was associated with signiﬁcantly better
24-month patency (78.9% vs. 50.1%) and lower
CD-TLR (9.1% vs. 28.3%). Both groups had similar
functional improvement; however, this was achieved
with a higher number of reinterventions in the an-
gioplasty arm. Interestingly, female patients and
those with diabetes had signiﬁcantly better patency
with the DCB compared with angioplasty. Further-
more, these results were achieved with low rates of
bailout stenting (7.3% in the DCB and 12.6% in the
angioplasty arms) and complications.
The authors should be congratulated for these
outstanding results in moderately long lesions.
Indeed, these ﬁndings are consistent with a 2-year
multicenter registry from Italy published by Micari
et al. (8). In that registry, patients with Rutherford
class 2 to 3, mean lesion length of 7.6 cm, and under-
going Admiral DCB had 72.4% primary patency. How-
ever, how generalizable are these results? Should DCB
be the default strategy for all femoropopliteal lesions,
even those that are long, calciﬁed, and occluded?
There are many options (Figure 1) with no head-to-
head randomized comparisons between various
technologies. Many consider angioplasty and nitinol
stenting with or without drug elution as standard of
therapy for femoropopliteal lesions. Although stents
pose a number of challenges, including restenosis,
fracture, and thrombosis (9), recent advances have
addressed many of these issues. For example, the
FIGURE 1 Current Options for Endovascular Treatment of Femoropopliteal Lesions
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The current approach to femoropopliteal lesions according to stent or no stent algorithm.
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2340wire-interwoven nitinol stent had 12-month patency
of 78.9% with no stent fracture reported by an inde-
pendent core laboratory (10). Similarly, Zilver
paclitaxel-eluting stents (Cook Medical, Bloomington,
Indiana) showed a 2-year primary patency of 74.8%
with 12-month fracture rate of 1.4% (11). Importantly,
in both studies, primary patency was deﬁned only by
peak systolic velocity and not CD-TLR. The inclusion
of CD-TLR, although clinically relevant, does create a
certain degree of bias in a nonblinded trial. In the
current trial, for example, a signiﬁcant portion of the
primary patency failure was driven by CD-TLR. How-
ever, this endpoint is frequently used in most
contemporary trials (4,12). Nevertheless, for lesions of
moderate length, DCB appears to have comparable
patency to that of most stents.
Unfortunately, data comparing DCB with bare or
drug-eluting nitinol stents are sparse. A single-center
randomized trial did compare DCB with drug-eluting
stents (DES) and found DES to have lower vessel
restenosis at 6 months only, but the study had many
limitations (13). Hence, the real challenge remains:
what is the best treatment option in this setting?
Nitinol self-expanding stents, DES, wire-interwoven
nitinol stents, covered stents, or DCB? Not to
mention, there are additional therapies such as
atherectomy or cutting balloon angioplasty (Figure 1).
There is also a signiﬁcant interest in combining
atherectomy with DCB therapy. Although there is no
level 1 evidence to support this approach, a few
single-center studies have shown early promise(14,15). The decision will undoubtedly rest with the
treating physician, taking a personalized approach to
each patient, his or her clinical presentation, and
lesion characteristics. Many factors should be
considered: clinical presentation (claudication vs.
critical limb ischemia), vessel size and lesion length,
degree of calciﬁcation, post–predilation angiogram,
number of runoff vessels, compliance with dual an-
tiplatelet therapy, and cost.
A few other points regarding the IN.PACT SFA trial
study design also merit attention. First, randomiza-
tion occurred after balloon pre-dilation, and data
regarding the number of patients excluded secondary
to failed angioplasty are not available. Therefore, the
general applicability of DCB in all comers is unknown.
Hence, DCB should likely be used after pre-dilation
with an undersized balloon. Second, although le-
sions up to 18 cm were allowed, the majority of
lesions (>95%) were <10 to 12 cm. Therefore, similar
to most stent trials, the safety and efﬁcacy of DCB
in moderate to long lesions is unknown. Third, the
investigators should be congratulated for using
core laboratory adjudication for all ultrasound and
CD-TLRs.
There remain many unanswered questions. What is
the pattern of restenosis or frequency of occlusion
after DCB intervention? What are the predictors of
restenosis or occlusion? Were there differences in
clinical presentation at the time of CD-TLR events
between the 2 groups? For example, the data on
mean time to the ﬁrst CD-TLR event are interesting
TABLE 1 Comparison of Drug-Coated Balloon Arms of LEVANT II and IN.PACT SFA Trials
LEVANT II DCB
(N ¼ 316)
IN.PACT SFA DCB
(N ¼ 220)
Balloon characteristics
Balloon Moxy (Lutonix, Inc. Maple Grove, Minnesota) Admiral (Medtronic, Santa Rosa, California)
Drug Paclitaxel Paclitaxel
Dose 2 mg/mm2 3.5 mg/mm2
Excipient Polysorbate, sorbitol Urea
Clinical characteristics
Age, yrs 67.8  10.0 67.5  10.0
Diabetes 43.4 40.5
Current smoking 35.1 38.6
Rutherford class 2 29.4 37.7
Rutherford class 3 62.7 57.3
Angiographic characteristics
Lesion length, cm 6.27  41.40 8.94  4.89
Severe calciﬁcation 10.4 8.1
Total occlusion 20.6 25.8
12-month outcomes*
Primary patency 65.2 82.2
24-month outcomes
Primary patency 58.6 78.9
Values are mean  SD or % unless otherwise indicated. *In the LEVANT II trial, primary patency was deﬁned as freedom from binary restenosis by duplex ultrasound or from the
need for target lesion revascularization (4). In the IN.PACT SFA trial, primary patency was deﬁned as freedom from binary restenosis by duplex ultrasound or from the need for
clinically driven target lesion revascularization (CD-TLR) (5).
DCB ¼ drug-coated balloon.
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2341and may indicate a different pattern of restenosis
between groups. Last, the higher mortality seen
among patients undergoing treatment with DCB is
likely by chance, but this will require further atten-
tion and follow-up.
The approval of DCB in the United States will
have a signiﬁcant effect on patient care and possibly
on outcomes. An important question remains: is this
a class effect, or are there differences between the 2
current approved devices (Table 1)? The 2 DCBs
differ in paclitaxel dose, the excipient, coating
technology, and balloon materials (16). Although
head-to-head data are not available, both studies
were similar with regard to baseline characteristics,
but the components of the primary outcome were
different, making any comparisons difﬁcult. In the
LEVANT II trial (Lutonix Paclitaxel-Coated Balloon
for the Prevention of Femoropopliteal Restenosis),
primary patency was deﬁned as freedom from bi-
nary restenosis by duplex ultrasound or from the
need for target lesion revascularization (4). Howev-
er, the IN.PACT SFA trial deﬁned primary patency as
freedom from binary restenosis by duplex ultra-
sound or from the need for CD-TLR (5). Importantly,
neither device has been studied in severe calciﬁca-
tion, in long lesions >20 cm, or in patients with
Rutherford class V and VI. Current global registries
with both DCBs will provide important insights tohelp guide clinicians. In the meantime, plain balloon
angioplasty for femoropopliteal lesions appears to
be clinically suboptimal and should rarely be per-
formed as a stand-alone treatment.
Fortunately, the scientiﬁc community and industry
have continued to pursue the endovascular treatment
of one of the most challenging arterial segments in
the body. Undoubtedly, DCBs have affected the care
of patients with peripheral artery disease, but they
have also posed a treatment conundrum. This is likely
to become even more complex as new devices like the
tack endovascular system or lithoplasty balloon
catheters become available in the United States. Yet,
the Affordable Care Act and other initiatives such as
the Bundled Payments for Care Improvement by the
U.S. Centers for Medicare & Medicaid Services also
will have as much if not a bigger effect on our deci-
sion making. To sustain these challenges, we must
encourage and demand head-to-head comparisons of
old, new, and future technologies so that the safest,
most efﬁcacious, and most cost-effective devices are
identiﬁed.
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